1. Home
  2. STRO vs BMN Comparison

STRO vs BMN Comparison

Compare STRO & BMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

N/A

Current Price

$8.76

Market Cap

159.5M

Sector

Health Care

ML Signal

N/A

Logo BlackRock 2037 Municipal Target Term Trust of Beneficial Interest

BMN

BlackRock 2037 Municipal Target Term Trust of Beneficial Interest

N/A

Current Price

$22.00

Market Cap

145.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
STRO
BMN
Founded
2003
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
159.5M
145.5M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
STRO
BMN
Price
$8.76
$22.00
Analyst Decision
Strong Buy
Analyst Count
14
0
Target Price
★ $44.69
N/A
AVG Volume (30 Days)
★ 291.0K
36.8K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $38,419,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.72
$21.28
52 Week High
$43.85
$27.96

Technical Indicators

Market Signals
Indicator
STRO
BMN
Relative Strength Index (RSI) 35.40 38.64
Support Level $8.11 $21.28
Resistance Level $10.77 $23.18
Average True Range (ATR) 0.85 0.51
MACD 0.14 -0.13
Stochastic Oscillator 17.01 6.61

Price Performance

Historical Comparison
STRO
BMN

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest

BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.

Share on Social Networks: